Literature DB >> 21528052

Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals.

Susan E Buskin1, Elizabeth A Barash, John D Scott, David M Aboulafia, Robert W Wood.   

Abstract

AIM: To examine trends in and correlates of liver disease and viral hepatitis in an human immunodeficiency virus (HIV)-infected cohort.
METHODS: The multi-site adult/adolescent spectrum of HIV-related diseases (ASD) followed 29 490 HIV-infected individuals receiving medical care in 11 U.S. metropolitan areas for an average of 2.4 years, and a total of 69 487 person-years, between 1998 and 2004. ASD collected data on the presentation, treatment, and outcomes of HIV, including liver disease, hepatitis screening, and hepatitis diagnoses.
RESULTS: Incident liver disease, chronic hepatitis B virus (HBV), and hepatitis C virus (HCV) were diagnosed in 0.9, 1.8, and 4.7 per 100 person-years. HBV and HCV screening increased from fewer than 20% to over 60% during this period of observation (P < 0.001). Deaths occurred in 57% of those diagnosed with liver disease relative to 15% overall (P < 0.001). Overall 10% of deaths occurred among individuals with a diagnosis of liver disease. Despite care guidelines promoting screening and vaccination for HBV and screening for HCV, screening and vaccination were not universally conducted or, if conducted, not documented.
CONCLUSION: Due to high rates of incident liver disease, viral hepatitis screening, vaccination, and treatment among HIV-infected individuals should be a priority.

Entities:  

Keywords:  Hepatitis B; Hepatitis C; Human immunodeficiency virus; Liver disease

Mesh:

Year:  2011        PMID: 21528052      PMCID: PMC3080714          DOI: 10.3748/wjg.v17.i14.1807

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

1.  Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV.

Authors:  Emma C Thomson; Eleni Nastouli; Janice Main; Peter Karayiannis; Joseph Eliahoo; David Muir; Myra O McClure
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

2.  A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals.

Authors:  Meredith S Shiels; Stephen R Cole; Gregory D Kirk; Charles Poole
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12       Impact factor: 3.731

3.  Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States.

Authors:  Karen A Hennessey; Andrea A Kim; Vivian Griffin; Nicoline T Collins; Cindy M Weinbaum; Keith Sabin
Journal:  J Urban Health       Date:  2008-07-12       Impact factor: 3.671

4.  Determination of the underlying cause of death in three multicenter international HIV clinical trials.

Authors:  Alan R Lifson; Waldo H Belloso; Cate Carey; Richard T Davey; Daniel Duprez; Wafaa M El-Sadr; Jose M Gatell; Daniela C Gey; Jennifer F Hoy; Eric A Krum; Ray Nelson; Daniel E Nixon; Nick Paton; Court Pedersen; George Perez; Richard W Price; Ronald J Prineas; Frank S Rhame; James Sampson; John Worley
Journal:  HIV Clin Trials       Date:  2008 May-Jun

5.  Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population.

Authors:  John D Scott; Anna Wald; Mari Kitahata; Elizabeth Krantz; Linda Drolette; Lawrence Corey; Chia C Wang
Journal:  AIDS Patient Care STDS       Date:  2009-11       Impact factor: 5.078

6.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

7.  Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007.

Authors:  Philip R Spradling; James T Richardson; Kate Buchacz; Anne C Moorman; Lyn Finelli; Beth P Bell; John T Brooks
Journal:  J Acquir Immune Defic Syndr       Date:  2010-03       Impact factor: 3.731

8.  Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.

Authors:  Nancy Crum-Cianflone; Gary Collins; Sheila Medina; Dean Asher; Richard Campin; Mary Bavaro; Braden Hale; Charles Hames
Journal:  Clin Gastroenterol Hepatol       Date:  2009-10-02       Impact factor: 11.382

9.  Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.

Authors:  James W T Cohen Stuart; Marieke Velema; Rob Schuurman; Charles A B Boucher; Andy I M Hoepelman
Journal:  J Med Virol       Date:  2009-03       Impact factor: 2.327

10.  Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study.

Authors:  Ellen Tedaldi; Lars Peters; Jacquie Neuhaus; Massimo Puoti; Jürgen Rockstroh; Marina B Klein; Gregory J Dore; Amanda Mocroft; Vincent Soriano; Bonaventura Clotet; Jens D Lundgren
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

View more
  8 in total

1.  Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta.

Authors:  Carmen Pittman; Sabrina Plitt; Ted Birse; Karen Doucette; Barbara Romanowski; Rya Cooper; Stan Houston; Stephen Shafran; Ameeta E Singh
Journal:  Can J Infect Dis Med Microbiol       Date:  2014       Impact factor: 2.471

2.  Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.

Authors:  Nimzing Gwamzhi Ladep; Patricia Aladi Agaba; Oche Agbaji; Auwal Muazu; Placid Ugoagwu; Godwin Imade; Graham Cooke; Sheena McCormack; Simon David Taylor-Robinson; John Idoko; Phyllis Kanki
Journal:  World J Gastroenterol       Date:  2013-03-14       Impact factor: 5.742

3.  Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.

Authors:  Jinjin Zhang; Andrea Mulvenon; Edward Makarov; Jill Wagoner; Jaclyn Knibbe; Jong Oh Kim; Natalia Osna; Tatiana K Bronich; Larisa Y Poluektova
Journal:  Biomaterials       Date:  2013-02-10       Impact factor: 12.479

4.  Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study.

Authors:  Robert S Hogg; Oghenowede Eyawo; Alexandra B Collins; Wendy Zhang; Shahab Jabbari; Mark W Hull; Viviane Dias Lima; Tareq Ahmed; Claire E Kendall; Keri N Althoff; Amy C Justice; Rolando Barrios; Jeannie Shoveller; Julio S G Montaner
Journal:  Lancet HIV       Date:  2017-03-03       Impact factor: 12.767

5.  Burden of vaccine-preventable diseases among at-risk adult populations in the US.

Authors:  Irina Kolobova; Mawuli Kwame Nyaku; Anna Karakusevic; Daisy Bridge; Iain Fotheringham; Megan O'Brien
Journal:  Hum Vaccin Immunother       Date:  2022-04-21       Impact factor: 4.526

6.  Vaccine uptake and barriers to vaccination among at-risk adult populations in the US.

Authors:  Irina Kolobova; Mawuli Kwame Nyaku; Anna Karakusevic; Daisy Bridge; Iain Fotheringham; Megan O'Brien
Journal:  Hum Vaccin Immunother       Date:  2022-05-10       Impact factor: 4.526

7.  Time trends of seroepidemiology of hepatitis C virus and hepatitis B virus coinfection in human immunodeficiency virus-infected patients in a Super Specialty Hospital in New Delhi, India: 2012-2014.

Authors:  Abha Sharma; Jasmin Halim; Tavleen Jaggi; Bibhabati Mishra; Archana Thakur; Vinita Dogra; Poonam Sood Loomba
Journal:  Indian J Sex Transm Dis AIDS       Date:  2016 Jan-Jun

8.  Characteristics of co-infections by HCV and HBV among Brazilian patients infected by HIV-1 and/or HTLV-1.

Authors:  Marcia Moreira; André Ramos; Eduardo M Netto; Carlos Brites
Journal:  Braz J Infect Dis       Date:  2013-09-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.